| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 8.6K | 4.3% | 8.4% |
| Total Income | 8.8K | 5.1% | 8.6% |
| Expenditure | 7.4K | 4.2% | 7.1% |
| PBT | 1.3K | 5.0% | 11.7% |
| Net Profit | 909.80 | 7.3% | 7.6% |
| OPM | 19.76% | 0.49pp | 13.44pp |
| NPM | 10.30% | 0.21pp | 0.07pp |
| EPS | 15.67 | 7.3% | 7.6% |
Aurobindo Pharma Reports 8.4% YoY Revenue Growth in Q3FY26
09 Feb 2026 · 9 Feb, 7:55 pm
Summary
Aurobindo Pharma Limited has announced its consolidated financial results for the quarter ended December 31, 2025, with an 8.4% YoY increase in revenue from operations. The company's EBITDA before R&D stood at INR 2,163 crores with a margin of 25.0%. Net profit for the period stood at INR 910 Cr. The company reported growth in Europe and US formulations revenue, with a strong net cash position and free cash flows generated during the quarter.
Key Highlights
- 1
Revenue from Operations increased by 8.4% YoY to INR 8,646 Cr
- 2
US formulations revenue increased by 2.2% YoY to INR 3,739 Cr
- 3
Europe formulations revenue increased by 27.4% YoY to INR 2,703 Cr
- 4
Growth Markets revenue remained flat YoY at INR 865 Cr
- 5
ARV revenue increased by 22.4% YoY to INR 376 Cr
- 6
Received final approval for 7 ANDAs from the USFDA
- 7
Strong net cash position as on 31-Dec-25 after appropriating cash for acquisition of Khandelwal laboratories is at USD 251mn
- 8
Free Cashflows of $118mn generated during the quarter
Management Comments
K. Nithyananda Reddy
Q3 reflected steady execution across Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term.
Informational and educational content only. Not investment advice.